| Recruiting | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | 2026-02-09 |
| Recruiting | The Multicentre Selective Lymphadenectomy Trial - 3 Cutaneous Melanoma, Stage III | N/A | 2025-10-01 |
| Recruiting | Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma Melanoma Metastatic | Phase 2 | 2025-03-06 |
| Recruiting | Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma | Phase 2 | 2024-06-21 |
| Recruiting | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Merkel Cell Carcinoma | Phase 2 | 2024-03-11 |
| Withdrawn | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma Mucosal Melanoma | Phase 2 | 2024-03-01 |
| Active Not Recruiting | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Mel Stage II Melanoma | Phase 2 | 2023-08-14 |
| Completed | Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanom Melanoma | Phase 2 | 2021-11-22 |
| Recruiting | Personalised Immunotherapy Platform Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | — | 2021-06-08 |
| Active Not Recruiting | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma Melanoma Stage III | Phase 2 | 2020-11-11 |
| Withdrawn | Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases Melanoma, In-Transit Metastasis of Cutaneous Melanoma | Phase 2 | 2020-05-20 |
| Recruiting | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) Melanoma Stage Iv | Phase 2 | 2019-08-14 |
| Completed | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Car Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer | Phase 2 | 2019-07-23 |
| Unknown | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma Melanoma | Phase 2 | 2017-11-08 |
| Active Not Recruiting | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases Melanoma, Brain Metastases | Phase 2 | 2014-11-04 |
| Active Not Recruiting | Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma Melanoma | Phase 2 | 2014-10-01 |